The evolutionary trade-off hypothesis: polyendocrine metabolic ovarian syndrome and late age at menopause

Polycystic Ovary Syndrome (PCOS), renamed as Polyendocrine Metabolic Ovarian Syndrome (PMOS), is clinically characterized by subfertility and metabolic dysfunction, yet its high prevalence across human populations presents a longstanding evolutionary paradox. This critical review utilizes the evolutionary trade-off hypothesis to propose that the genetic architecture of PMOS historically conferred survival advantages in harsh ancestral environments through metabolic thrift and the adaptive spacing of pregnancies. Rather than evolving specifically to extend the reproductive lifespan, the delayed ovarian senescence and later age at natural menopause (ANM) observed in PMOS are proposed to be pleiotropic byproducts of this highly conserved cellular resilience. Current genomic data reveals a robust overlap between PMOS susceptibility loci and genetic determinants of delayed menopause. Specifically, alleles conferring high-fidelity DDR pathway (e.g., MCM8, RAD50) and dampened gonadotropin signaling (e.g., FSHB) actively decelerate ovarian aging. Furthermore, this reviewe highlights an “immunogenetic paradox” wherein a constitutively high inflammatory baseline, which typically drives rapid follicular depletion, is counterbalanced by supraphysiological anti-mullerian hormone (AMH) levels. This targeted antagonism physically “stockpiles” the primordial reserve, locking follicles in developmental stasis. Consequently, the hallmark features of PMOS, including follicular arrest and hyperandrogenism, are not merely biological defects, but the modern maladaptive manifestations of an ancient biological strategy designed to prevent premature ovarian exhaustion. Not applicable.